SNSE

Company Overview — What Does Sensei Biotherapeutics, Inc. Do?

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Sensei Biotherapeutics, Inc. (SNSE) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John K. Celebi and employs approximately 40 people. With a market capitalization of $44M, SNSE is one of the notable companies in the Healthcare sector.

Sensei Biotherapeutics, Inc. (SNSE) Stock Rating — Reduce (April 2026)

As of April 2026, Sensei Biotherapeutics, Inc. receives a Reduce rating with a composite score of 34.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SNSE ranks #2,150 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sensei Biotherapeutics, Inc. ranks #247 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SNSE Stock Price and 52-Week Range

Sensei Biotherapeutics, Inc. (SNSE) currently trades at $29.89. The stock lost $0.64 (2.1%) in the most recent trading session. The 52-week high for SNSE is $36.76, which means the stock is currently trading -18.7% from its annual peak. The 52-week low is $0.25, putting the stock 11856.0% above its annual trough. Recent trading volume was 12K shares, suggesting relatively thin trading activity.

Is SNSE Overvalued or Undervalued? — Valuation Analysis

Sensei Biotherapeutics, Inc. (SNSE) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.18x, versus the sector average of 2.75x.

At current multiples, Sensei Biotherapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Sensei Biotherapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Sensei Biotherapeutics, Inc. (SNSE) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -127.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -103.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SNSE Debt, Balance Sheet, and Financial Health

Sensei Biotherapeutics, Inc. has a debt-to-equity ratio of 23.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.06x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $11M.

SNSE has a beta of -3.65, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Sensei Biotherapeutics, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Sensei Biotherapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sensei Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-16.72. Net income for the quarter was $-24M. Operating income came in at $-25M.

In FY 2025, Sensei Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-16.72. Net income for the quarter was $-21M. Operating income came in at $-22M.

In Q3 2025, Sensei Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.62. Net income for the quarter was $-5M. Operating income came in at $-5M.

In Q2 2025, Sensei Biotherapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-3.91. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, Sensei Biotherapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing SNSE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SNSE Dividend Yield and Income Analysis

Sensei Biotherapeutics, Inc. (SNSE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SNSE Momentum and Technical Analysis Profile

Sensei Biotherapeutics, Inc. (SNSE) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 9/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SNSE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sensei Biotherapeutics, Inc. (SNSE) ranks #247 out of 838 stocks based on the Blank Capital composite score. This places SNSE in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SNSE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SNSE vs S&P 500 (SPY) comparison to assess how Sensei Biotherapeutics, Inc. stacks up against the broader market across all factor dimensions.

SNSE Next Earnings Date

No upcoming earnings date has been announced for Sensei Biotherapeutics, Inc. (SNSE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SNSE? — Investment Thesis Summary

The quantitative profile for Sensei Biotherapeutics, Inc. suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 32/100) increases portfolio risk.

In summary, Sensei Biotherapeutics, Inc. (SNSE) earns a Reduce rating with a composite score of 34.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SNSE stock.

Related Resources for SNSE Investors

Explore more research and tools: SNSE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SNSE head-to-head with peers: SNSE vs AZN, SNSE vs SLGL, SNSE vs VMD.